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Abstract
Background: Prostate cancer is one of the leading causes of cancer deaths among men. New gene expressed in
prostate (NGEP), is a prostate-specific gene expressed only in normal prostate and prostate cancer tissue. Be-
cause of its selective expression in prostate cancer cell surface, NGEP is a potential immunotherapeutic target.
To target the NGEP in prostate cancer, it is essential to investigate its expression in prostate cancer cells.
Methods: In the present study, we investigated NGEP expression in LNCaP and DU145 cells by real time and
RT-PCR, flow cytometric and immunocytochemical analyses.
Results: Real time and RT-PCR analyses of NGEP expression showed that NGEP was expressed in the
LNCaP cells but not in DU145 cells.  The detection of NGEP protein by flow cytometric and immunocytochem-
istry analyses indicated that NGEP protein was weakly expressed only in LNCaP cell membrane.
Conclusion: Our results demonstrate that LNCaP cell line is more suitable than DU145 for NGEP expression
studies; however, its low-level expression is a limiting issue. NGEP expression may be increased by androgen
supplementation of LNCaP cell culture medium.
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Introduction
Prostate cancer is the second most com-
mon cause of cancer mortality and one of
the leading cause of cancer deaths among
men (1). It develops primarily in men over
fifty, however, the onset of prostate cancer
vary widely across the world population.
The incidence of prostate cancer in Eastern
countries is lower than the Western coun-
tries (2).
Standard treatments for localized prostate
cancer include surgery, radiotherapy, and
active monitoring. The current therapies for
advanced and metastatic cancer are hor-
mone therapy an d chemotherapy (3,4).
However, these therapies are currently una-
ble to completely eliminate androgen-
independent prostate cancer cells that re-
main after androgen ablation therapy in
metastatic prostate cancer. Androgen inde-
pendent prostate cancer progression and
metastasis are major causes of prostate can-
cer deaths (5,6).  Therefore, novel ap-
proaches for the treatment of prostate can-
cer are essential. Previous studies have
demonstrated that vaccine and targeted
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therapy could be promising efficacious
treatments for this type of cancer (7). Thus,
identification of the specific tumor markers
for prostate cancer targeted therapy is cru-
cial.
The recent studies have been shown that
prostate specific antigen (PSA) in both
prostate tissue and other normal tissues
such as kidney, liver, esophagus, stomach,
small intestine, colon, brain, and lung (8,9).
These data showed that PSA cannot be
considered as a specific target for immuno-
therapy of prostate cancer and researchers
tend to identify particular markers for such
idea.
Several studies have reported that NGEP
that also called ANO7 is expressed specifi-
cally in prostate tissue. In an immunohisto-
chemical analysis, it was shown that NGEP
is highly expressed in low-grade prostate
cancers (10,11). NGEP is a cell membrane
protein of anoctamin/TMEM16 family that
functions as calcium-activated chloride
channels (12). Moreover, this antigen is the
most attractive tumor marker for immuno-
therapy approaches because of its potent
immunogenicity in addition to prostate tis-
sue-restricted expression (13,14). There are
two isoforms of NGEP due to different
mRNA splicing. The smaller transcript en-
codes a 179-amino acid cytoplasmic pro-
tein (NGEP-S) and the larger transcript en-
codes a 933-amino acid polytopic mem-
brane protein (NGEP-L) (10,13).
NGEP is important because expresses on-
ly in prostate tissue and therefore appropri-
ate marker for prostate cancer immunother-
apy. To target the NGEP in prostate cancer
cells for future studies, it is essential to in-
vestigate NGEP expression in these cells.
In the present study, we investigated NGEP
expression in two standard prostate cancer
cell lines; LNCaP and DU145, as andro-
gen-dependent (15) and androgen-
independent (16) cells, respectively.
Methods
Cell culture
The human prostate cancer cell lines,
LNCaP and DU145, were purchased from
Pasteur Institute of Iran. These cell lines
were cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) (GIBCO, Rock-
ville, MD) supplemented with 10% fetal
bovine serum (GIBCO) and 100 µg/ml pen-
icillin/streptomycin (GIBCO). The cells
were incubated in a 5% CO2, 95% air hu-midified incubator at 37 ◦C.
RNA isolation, RT-PCR and real time
PCR
Total RNA isolation from LNCaP and
DU145 cell lines were  performed using
TRIzol reagent (Invitrogen, Carlsbad,
USA) followed by phenol-chloroform ex-
traction and isopropanol precipitation. Ex-
tracted RNA was checked by spectropho-
tometry, and RNA integrity was confirmed
by visualization of 28S and 18S bands on
1% of an agarose gel. The RNA was tran-
scribed using the reverse transcription sys-
tem (Transcriptor high fidelity cDNA syn-
thesis kit; was obtained from Roche, IN,
USA). The following primers were applied
in PCR experiments forward NGEP: 5ʹ-
TTC CTG CCG CGT GC C TAC TA-3ʹ,
reverse NGEP: 5’-GGT CTG GGA ATA
ATG TCC ATC GTC-3’; forward GAPDH:
5’-TTGCCATCAATGACCCCTTCA-3’,
reverse GAPDH: 5’-CGCCCCACTTGATT
TTGGA-3’; forward b2 microglobulin: 5’-
CCTGAATTGCTATGTGTCTGGG-3’,
reverse β2 microglobulin: 5’-TGATGC
TGCTTACATGTCTCGA-3’. Sizes of
NGEP, GAPDH and β2 microglobulin
mRNA detected by designed primers were
160, 174 and 244 base pairs, respectively.
PCR was performed using HotStarTaq Plus
DNA Polymerase (QIAGEN, CA, USA)
and the mRNA expressions of the NGEP,
GAPDH and β2 microglobulin were as-
sayed using the following PCR cycling pro-
tocol: initial denaturation for 5 min at 95°C,
35 cycles of denaturation 10s at 94°C, an-
nealing for 30s at 57°C, 30s at 72°C, and
finally, elongation for 7 min at 72°C.
Real-time PCR was carried out using the
AccuPower 2X Greenstar qPCR Master
Mix (BIONEER, Korea). All PCR reac-
tions were performed in a total volume of
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20µl with the following sequence: one cy-
cle of pre-denaturation for 5 min at 95 °C
and 45 amplification cycles (5s of denatura-
tion at 95°C and 35s of annealing and ex-
tension at 57°C and 72°C). The threshold
cycle (Ct) values obtained from experi-
ments were used to indicate the fractional
cycle numbers at which the amount of am-
plified target reached a fixed threshold. The
amount of NGEP mRNA in LNCaP cells
was normalized to the internal control
(GAPDH) and evaluated relative to DU145
cells. Relative expression levels were pre-
sented as the fold change that calculated
using ΔΔCt.
Flow cytometric analysis
The cells were harvested by 0.25% Tryp-
sin-EDTA solution (1X) (GIBCO), washed
and resuspended in ice cold PBS, contain-
ing 5% BSA and 1% sodium azide. Two
preparations of rabbit polyclonal antibodies
(anti-NGEP-p1 and -p2 antibodies) against
NGEP-L extracellular parts:      anti-NGEP-
P1 (specific for residues 669-684) and anti-
NGEP-P2 (specific for residues 691-705)
designed by an immuno-bioinformatics ap-
proach were produced in the Biotechnology
laboratory of Iran University of Medical
Sciences as primary antibodies, (data not
shown). The antibodies were diluted in
3%BSA/PBS and added in parallel to cell
suspensions. Cell suspensions were incu-
bated for 30 min at room temperature. After
washing 2 times with 3%BSA/PBS, the
cells were stained with a solution of 1:160
FITC-conjugated goat anti-rabbit IgG
(Sigma, St. Louis, MO, USA) in the same
buffer for 30 min, and then washed 2 times.
The cells which have not been treated with
primary antibodies used as negative con-
trol. PBS and equal concentration of IgG
fraction from pre-immunized rabbit serum
applied as negative controls instead of the
primary antibody.
Binding of the cells (1x105) to anti-
NGEP-p1 and -p2 antibodies was investi-
gated by flow cytometry (Partec, Germany)
and data were analyzed using flomax soft-
ware. The dead cells were excluded from
the analysis based on scatter profile.
Immunocytochemistry
The cells were cultured in 96 well plates
and grown for 24 h in 5% CO2/95% airhumidified incubator at 37°C. The cells
were then washed with PBS, fixed for 20
min in 4% formaldehyde, washed and in-
cubated with 3% BSA/PBS for 30 min at
room temperature. Subsequently cells were
washed and treated with primary antibodies
(anti-NGEP-p1 and p2 antibodies) diluted
1:2 for 1 hour at room temperature. The
cells were then washed and incubated at
room temperature for 1 hour with a dilution
of 1:160 FITC-conjugated goat anti-rabbit
IgG (Sigma), washed and analyzed using
an inverted fluorescence microscope
(Olympus, Japan).  PBS and equal concen-
tration of IgG fraction from pre-immunized
rabbit serum applied as negative controls
instead of the primary antibody.
Results
Expression studies of the NGEP were
performed by RT-PCR on cDNA prepara-
tion from the prostate cancer cell lines. Us-
ing RT-PCR, we showed NGEP expression
in LNCaP, but it was not detectable in
DU145 cells (Fig. 1). To compare relative
NGEP expression of LNCaP to DU145
cells, we performed real time RT-PCR as-
say. The GAPDH normalized results
showed that LNCaP cells express NGEP
26.13 fold higher than that of DU145 cells.
Fig. 1. RT-PCR analysis of prostate cancer cell
lines; LNCaP and DU145 cells.  Lane 1 shows
NGEP expression, lanes 2 and 3 show GAPDH and
b2 microglobulin expression respectively.
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As illustrated in Fig. 2, flow cytometric
analysis of the LNCaP line with anti
NGEP-p1 and -p2 antibodies against NGEP
showed that only 8% and 5% of the cells
were stained with these two antibodies, re-
spectively. Whereas, no staining was seen
in DU145 cells and expression of NGEP
protein was negative in DU145 cells.
We also investigated staining pattern of
NGEP in prostate cell lines treated with
anti NGEP-p1 and -p2 antibodies by im-
munocytochemistry. Immunocytochemical
analysis of LNCaP cell line both anti
NGEP-p1 and -p2 antibodies showed weak
Fig. 2. Flow cytometric analysis of NGEP expression in prostate cancer cell lines. A: LNCaP cells and B: DU145 cells
treated with anti NGEP-p1 and p2 antibodies. Negative control: the cells not treated with primary antibodies (anti-
NGEP-p1 and or p2 antibody).
Fig 3: Images of LNCaP and DU145 cell lines taken by light microscopy (A,C,E) and immunofluorescence (B,D,E) when
treated with anti-NGEP-p2 antibody. A and B; LNCaP cells not treated with anti-NGEP-p2 antibody (negative control), C
and D; LNCaP cells treated with anti-NGEP-p2 antibody, D and E; DU145 cells treated with anti-NGEP-p2 antibody.
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green fluorescence signals but in DU145
cells there were very weak or no signal of
fluorescence and observed ghost of cells as
shown at Fg. 3 by anti-NGEP-p2 antibody.
Discussion
In an immunohistochemical study, we
demonstrated that NGEP expression level
was decreased from low-grade to high-
grade prostatic adenocarcinoma samples,
indicating that NGEP can be a valuable po-
tential prognostic tumor antigen and there-
fore an attractive target for antibody-based
immunotherapy (11). Other previous stud-
ies have also shown that NGEP is an an-
drogen-dependent and differentiation anti-
gen that is highly expressed in well differ-
entiated prostate cancer tissues in compari-
son to the poor differentiated prostate can-
cer cells (17). The LNCaP cell line is more
differentiated than PC3 and DU145 cell
lines as evidenced by production of PSA
and its response to androgens (18). The RT-
PCR analysis has shown NGEP expression
in LNCaP cell line and prostate cancer
specimens, however, NGEP mRNA not
detected in the PC3 cell line (10). It has
been shown that NGEP antigen was located
in the plasma membrane and its concentra-
tion increased at cell contact regions which
play an important role in cell-cell interac-
tions (13).
Consideration to NGEP significance for
prostate cancer immunotherapy, in the pre-
sent study, we evaluate its expression at
molecular and protein levels in prostate
cancer cells using RT-PCR, flow cytometry
and immunocytochemistry techniques.
Our investigation on the NGEP gene ex-
pression in LNCaP and DU145 cells re-
vealed that NGEP was expressed in LNCaP
cell, while it not in DU145 cells. Our find-
ing highlighted previous data showing that
NGEP is expressed in more differentiated
and predominantly androgen-dependent
prostate cancer cells (11).
NGEP expression was examined by
Cereda et al  using flow cytometric analysis
in six established prostate cancer cell lines
including PR-22, DU145, 22rV1, MDA-
PCA-2b, LNCaP and PC3, demonstrating
very low level of expression in three cell
lines (PR-22; 2.68%, DU145; 11.42% and
PC3; 7.32%), moderate expression in two
cell lines (22rv1;42.47%,  LNCaP; 35%)
and high level of expression in one cell line
(MDA-PCA-2b; 71.42%) (14). In the pre-
sent study, we measured the expression of
NGEP in LNCaP and DU145 using flow
cytometric analysis and immunocytochem-
istry. The polyclonal antibodies against ex-
tracellular domains of NGEP-L were pro-
duced in our laboratory (data not shown).
To show the specificity of polyclonal anti-
bodies against designed peptides of NGEP-
L (anti-NGEP-p1 and -p2 antibody) and to
determine any nonspecific binding in pros-
tate tissue by these antibodies, we were
able to block completely the specific bind-
ing of antibodies to NGEP protein by ap-
propriate concentrations of peptides. No
background staining was observed using
these antibodies in immunohistochemistry
analysis, indicating that these polyclonal
antibodies were specific for the regions to
which they were produced (data not
shown).
To target the tumor antigen, it is im-
portant to produce antibodies bound to ex-
tracellular domains of membrane protein
but not intracellular domains. In previous
studies antibody produced against NGEP
was for intracellular domain (13,14), while
in this study antibodies produced in our la-
boratory were for extracellular domains.
Moreover, our finding was in controversy
with previous studies in terms of NGEP
protein expression level. Our data indicated
that NGEP expressed at low levels in the
cell membrane of intact LNCaP cells at 8%
and 5% detected by anti-NGEP-p1 and p2
antibodies, respectively, and no expression
was observed in DU145 cells. Whereas, the
study performed by Cereda et al using anti-
body produced against intracellular domain
showed the NGEP expression in cell mem-
branes of both LNCaP and DU145 cells at
35% and 11.42%, respectively in permea-
ble condition (14). Taken together, our re-
sult showed that LNCaP cells in native
NGEP as a potential target for immunotherapy
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condition could not be a good target for
immunotherapy. Moreover, attempts to de-
tect NGEP protein in LNCaP cells by west-
ern blot were unsuccessful (13).
On the other hand, our finding was in
agreement with RT-PCR analysis of Bera
and et al. (10) determining that NGEP gene
was expressed only in LNCaP cell line, not
in PC3 and DU145 cells. Our data also con-
firmed previous study (10) reporting that
NGEP gene was not expressed in androgen-
independent DU145 cell line, while it was
detectable in sensitive androgen LNCaP
cells.
It has been reported that the LNCaP pros-
tate cancer cells express the androgen re-
ceptors and PSA (19). As PSA is almost
exclusively expresses through the androgen
receptor signaling pathway (19), it may
suggest that NGEP gene expression also
depends upon these receptor signaling
pathways and can be regulated by androgen
receptors.
On the other side, NGEP-L is a mem-
brane antigen which exclusively detected in
normal prostate, benign prostatic hyper-
plasia, high-grade prostatic intraepithelial
neoplasia and prostatic adenocarcinomas
with variety of levels (11). This relatively
higher level of NGEP expression in pros-
tate tissues (11,17) compared to prostate
cell lines , can be due to repeated passages
of cell lines in vitro and the growth of cells
in androgen-free media which may finally
decrease the NGEP expression in prostate
cell lines.
The further studies are required to inves-
tigate low NGEP expression in androgen
sensitive cells. It is suggested that LNCaP
to be cultured in a medium containing an-
drogens such as dihydrotestosterone and
evaluated NGEP expression.
Conclusion
NGEP protein can be used as an attractive
marker in immunotherapy of prostate can-
cer. Our results showed that LNCaP cell
line is more suitable than DU145 for NGEP
expression studies. However, the NGEP
expresses in low level in LNCaP cell line;
hence further studies need to be conducted.
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